Hangzhou Biotest Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	439.03	519.74	435.93	1,894	1,811	855.9
Other Revenue	39.67	39.67	6.18	7.23	7.09	9.47
Revenue	478.69	559.4	442.11	1,901	1,818	865.37
Revenue Growth (YoY)	-7.70%	26.53%	-76.74%	4.57%	110.09%	314.37%
Cost of Revenue	251.1	286.6	269.6	940.21	705.47	242.57
Gross Profit	227.59	272.81	172.51	960.93	1,113	622.8
Selling, General & Admin	99.55	85.9	79.21	86.09	69.63	42.36
Research & Development	77.31	63.57	80.48	108.21	61.92	41.32
Other Operating Expenses	8.61	7.05	4.95	19.49	16.84	9.69
Operating Expenses	187.04	160.05	168.31	208.2	151.61	96.6
Operating Income	40.55	112.76	4.21	752.73	961	526.2
Interest Expense	-0	-0.03	-0.14	-0.19	-0.68	-0.47
Interest & Investment Income	45.41	57.28	76.9	51.91	15.36	1.4
Currency Exchange Gain (Loss)	11.44	11.44	13.07	111.92	-15.48	-17.16
Other Non Operating Income (Expenses)	-3.16	-1.92	-0.59	-1.1	-0.87	-0.67
EBT Excluding Unusual Items	94.24	179.52	93.46	915.26	959.34	509.3
Gain (Loss) on Sale of Investments	0.26	0.26	-	0.06	0.84	-
Gain (Loss) on Sale of Assets	-0.03	-0.33	0	-	-	-0.03
Asset Writedown	8.23	-	-6.35	-18.78	-0	-0
Other Unusual Items	15.47	15.47	28.77	5.35	8.45	5.06
Pretax Income	118.18	194.92	115.88	901.9	968.63	514.33
Income Tax Expense	17.65	28.14	10.58	128.33	132.87	79.36
Earnings From Continuing Operations	100.52	166.78	105.3	773.56	835.76	434.97
Minority Interest in Earnings	2.04	2.74	1.31	0.07	-2.17	0.18
Net Income	102.57	169.52	106.61	773.63	833.59	435.15
Net Income to Common	102.57	169.52	106.61	773.63	833.59	435.15
Net Income Growth	-1.65%	59.01%	-86.22%	-7.19%	91.56%	1441.52%
Shares Outstanding (Basic)	157	147	149	149	121	112
Shares Outstanding (Diluted)	157	147	149	149	121	112
Shares Change (YoY)	6.66%	-1.23%	-0.10%	23.14%	8.33%	-0.01%
EPS (Basic)	0.65	1.15	0.71	5.18	6.87	3.89
EPS (Diluted)	0.65	1.15	0.71	5.18	6.87	3.89
EPS Growth	-7.79%	61.00%	-86.21%	-24.64%	76.84%	1454.28%
Free Cash Flow	14.09	-116.23	74.96	524.29	707.92	388.38
Free Cash Flow Per Share	0.09	-0.79	0.50	3.51	5.84	3.47
Dividend Per Share	0.714	1.071	0.571	1.571	2.143	-
Dividend Growth	-23.07%	87.50%	-63.64%	-26.67%	-	-
Gross Margin	47.55%	48.77%	39.02%	50.54%	61.20%	71.97%
Operating Margin	8.47%	20.16%	0.95%	39.59%	52.86%	60.81%
Profit Margin	21.43%	30.30%	24.11%	40.69%	45.85%	50.28%
Free Cash Flow Margin	2.94%	-20.78%	16.95%	27.58%	38.94%	44.88%
EBITDA	59.26	134.03	28.88	772.63	969.2	531.69
EBITDA Margin	12.38%	23.96%	6.53%	40.64%	53.31%	61.44%
D&A For EBITDA	18.71	21.27	24.68	19.9	8.2	5.48
EBIT	40.55	112.76	4.21	752.73	961	526.2
EBIT Margin	8.47%	20.16%	0.95%	39.59%	52.86%	60.81%
Effective Tax Rate	14.94%	14.44%	9.13%	14.23%	13.72%	15.43%
Revenue as Reported	478.69	559.4	442.11	1,901	1,818	865.37
Advertising Expenses	-	2.82	4.21	3.19	1.63	2.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.